Maze Therapeutics
Market cap $1.80B 54.7M shares (10-Q, Nov 4, 2026) × $32.87 close Nov 17, 2026
Most recent annual filing: 2026-03-25
- Repinatrabit Otsuka Ph3 readoutLate 2026Repinatrabit Otsuka Ph3 readout, Late 2026, notable
- MAZE corporate updateNov 2026MAZE corporate update, Nov 2026, routine
- MZE829 readout1H 2027MZE829 readout, 1H 2027, major
- Inaxaplin Vertex interimEarly 2027Inaxaplin Vertex interim, Early 2027, major
- MZE782 Ph2 topline2027MZE782 Ph2 topline, 2027, material
- MZE829 pivotal start1H 2027MZE829 pivotal start, 1H 2027, notable
- MZE782 Ph2 start1H 2027MZE782 Ph2 start, 1H 2027, routine
- AZD2373 AstraZeneca Ph2b readoutOct 2027AZD2373 AstraZeneca Ph2b readout, Oct 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
MZE782
MZE001
Technology platforms
Compass
Genetics-driven drug discovery platform that identifies and characterizes genetic variants associated with health and disease and determines how these drive risk for or protection against disease in specific patient groups through variant functionalization; purpose-built to inform all phases of drug discovery and development including clinical trial design; focus areas: kidney and metabolic diseases
Capital (as filed)
- Cash
- $154M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $236M Sep 30, 2026
- Long-term investments
- $87.3M Sep 30, 2026
- Operating cash flow
- −$32.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $477M cash, runway into 2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-10 UPDATE: Maze Therapeutics (MAZE) - Fifty Patients and a Quiet ATM 🔒 Paid
- 2026-11-03 Maze Therapeutics (MAZE) - Scientific Deep Dive for MZE829, MZE782 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Maze Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-11-03 Watch Maze Therapeutics (MAZE) - Scientific Deep Dive for MZE829, MZE782 and Pipeline Products APOL1 inhibition is validated but MZE829's broad-AMKD case rests on only four FSGS patients and eight others averaging -16.5%, while Vertex leads with more data, Breakthrough designation, and an accelerated-approval interim due before Maze's pivotal even starts; at ~$1.47B EV the market already prices a credible #2 with no margin of safety.
- 2026-11-10 Watch UPDATE: Maze Therapeutics (MAZE) - Fifty Patients and a Quiet ATM HORIZON enrollment to 50+ patients improves the quality of the coming binary readout but provides no new efficacy data; at ~$35 and ~$1.7B EV the stock has moved above the probability-weighted value with no new evidence, so the WATCH stance is maintained pending the non-FSGS cohort clearing ≥30% uACR with uPCR disclosed.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“In addition, we plan to initiate a pivotal trial of MZE829 in the first half of 2027, subject to regulatory feedback.”
matched to MZE829 · readout other
-
-
-
“In addition, we plan to initiate a pivotal trial of MZE829 in the first half of 2027, subject to regulatory feedback.”
matched to MZE829 · readout other
-
-
-
“Based on the topline results from HORIZON, Maze plans to initiate a pivotal trial in the first half of 2027, subject to regulatory feedback.”
matched to MZE829 · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (18)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseMaze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD updateHORIZON just enrolled 50+ patients across all three AMKD cohorts — more than triple the initial 15-patient interim cut and well above the 10–15/cohort target — setting up a materially stronger dataset for the early-2027 readout than the writeup modeled.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 3, 2026ReleaseMaze Therapeutics to Participate in Upcoming Investor Conferences
- Oct 16, 20268-KCurrent report: material agreement, unregistered sale of equity
- Aug 17, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jun 10, 20268-KCurrent report: shareholder vote
- May 22, 20268-KCurrent report: officer / director change
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Apr 22, 20268-KCurrent report: other events · EX-99.1
- Apr 22, 2026424B5Prospectus supplement (offering)
- Mar 25, 20268-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1
- Mar 25, 202610-KAnnual report
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026EFFECTRegistration effective
- May 12, 2026POS AMPost-effective amendment
- Apr 28, 2026ARSAnnual report to shareholders
- Apr 1, 2026SCHEDULE 13GPassive >5% holder (13G)